Form D · Biotechnology
Erasca, Inc.
San Diego, CA · CIK 0001761918
Offering snapshot reported Apr 30, 2020 · SEC filing
- Reported sold
- $125M Offering amount: $375M
- Investors reported
- 46 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 15, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 30, 2020 | Initial | $125,405,005 | No comparison | 46 | SEC filing |
| Mar 11, 2019 | Amendment | $58,278,287 | $16,920,050vs Jan 15, 2019 | 41 | SEC filing |
| Jan 15, 2019 | Initial | $41,358,237 | No comparison | 27 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-366079
Source: Form D, filed Apr 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James A. Bristol, Ph.D. | Director |
| Alexander W. Casdin | Director |
| Valerie Harding Start | Director |
| Jonathan E. Lim, M.D. | Director |
| Pratik S. Multani, M.D. | Director |
| Gary Yeung, Cfa | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
10835 Road To The Cure, Ste. 140
San Diego, CA, 92121
San Diego, CA, 92121